fda compounding semaglutide update today Important Update: Changes to Compounded Availability US FDA proposes curbs on

Most PBMs now require prior authorization (PA) for GLP-1s, but not all criteria is created equal

Their filing for FDA approval of CagriSema in early 2026 puts them on track for a potential approval decision by late 2026 or early 2027

By signaling to your brain that you're full and satisfied, GLP-1s help reduce cravings and suppress your appetite

It says reviewers frequently reject requests when the prescriber has not documented a specific BMI measurement, a comorbidity diagnosis, or an adequate timeline of prior weight loss intervention attempts

Apart from resmetirom, recently approved by the FDA for use in patients with MASH with moderate to advanced liver fibrosis, there are no other therapeutic options for this disease 92

Also learning about Emotional Disregulation has been amazing